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Abstract Secondary prevention of colorectal cancer, as
opposed to primary prevention, indicates that a person has
already had the disease and there are steps being taken to
prevent cancer recurrence, usually as metachronous tumors.
This generally involves annual surveillance with colonoscopy
aftersurgicalremovaloftheinitialcancerifsomeaspectofthe
colon remains. However, some familial cases may involve
other modalities, such as cyclooxygenase inhibitors, as an
adjunct after the initial operation. Genetic testing in suspected
familial cases may identify candidates for secondary preven-
tion. The timing for secondary prevention is criticalto prevent
recurrent advanced disease, which is detrimental to patient
survival. Recommendations are often empiric, but some cases
are based on the biological behavior of the tumor. Close
follow-up with a competent health care provider, such as a
gastroenterologist, is necessary to help prevent recurrence.
Keywords Colorectalcancer.Lynchsyndrome.
HNPCC(hereditarynonpolyposiscolorectal cancer).
Familialcancer.Secondaryprevention.Colonoscopy.
Coloncancergenetics.Colorectalcancerscreening
Introduction
Colorectal cancer may be a devastating disease for patients
if it is not discovered early in its progression. With 146,970
new cases of colorectal cancer and 49,920 deaths attributed
to colorectal cancer in 2009 in the United States, prevention
of this relatively common cancer will be key to reducing its
incidence [1]. Indeed, some experts attribute the modest
decline in colorectal cancer incidence in the United States to
efforts put forth in screening the general healthy population
overthe age of50years,withremoval ofadenomatous polyps
as its primary precursor lesion, and there is evidence for an
increased colorectal cancer rate among the nonscreened
populationundertheageof50years[2, 3]. Recommendations
for screening have been updated recently and are based on
tests that can detect cancers and those that can detect
adenomatous polyps [4••]. These tests have varying rates for
detecting colonic lesions; CTcolonography and colonoscopy
have the best detection rates, and colonoscopy has the added
utility of removing and sampling lesions.
Secondary prevention (also known as surveillance)
implies a patient has already had colorectal cancer and
active steps are being taken to prevent cancer recurrence,
usually as metachronous tumors. The tests used for
primary screening no longer apply to secondary preven-
tion, as direct visualization of any remaining colon is the
only option in these high-risk patients [4••, 5•, 6]. These
patients are “taken out” of the general population pool that
has never had colorectal cancer and are specifically targeted
for surveillance based on their history of colorectal cancer.
Some aspects of primary prevention, such as eating a
healthy, balanced diet (ie, low in fat, high in fiber, rich in
omega-3 oil and vitamin D or calcium) and exercising
regularly, still apply to secondary prevention [7]. However,
these steps are not enough because biological behavior and
genetic factors may predominate in the drive toward cancer
recurrence, and medical surveillance by colonoscopy is
critical to prevent recurrence and death [4••, 5•, 6, 7, 8•, 9–
14]. In patients with inflammatory bowel disease such as
ulcerative colitis, the risk of colorectal cancer begins to
increase after 8 to 10 years and increases approximately 1%
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[15]. In patients with ulcerative colitis, the only option for
treating primary colorectal cancer is colectomy, so for these
patients, secondary prevention is unnecessary.
The main risks underlying the development of recurrent
tumors are largely genetic and are less likely to be environ-
mental[5•, 8•, 15]. In a patient who has had colorectal cancer,
the risk of a metachronous tumor is elevated, likely similar to
levels of a person without cancer who has a first-degree
relative under the age of 45 with colorectal cancer (a lifetime
risk of 33%) [8•]. Treatment of the initial tumor does not
affect the occurrence of a second tumor; that is, although
surgical resection and radiochemotherapy may treat the
primary tumor, they do not prevent the occurrence of a
secondary metachronous tumor [5•, 16]. Patients need a
dedicated and consistent surveillance program to reduce their
chance of death from metachronous colorectal cancer [2, 5•,
6]. The timing of secondary prevention is critical to prevent
recurrent advanced disease, which is detrimental to patient
survival. Recommendations often are empiric, but in some
cases, they are based on the biological behavior of the tumor.
In general, annual colonoscopy with removal and sampling of
lesions is recommended.
Secondary Prevention for Familial Colorectal
Cancer Syndromes
Familial colorectal cancer syndromes pose a particularly high
risk for metachronous tumors because of the nature of
germline mutations in critical growthpathways thataccelerate
polyp and cancer growth [5•, 8•, 15, 17]. These syndromes
include adenomatous syndromes (eg, familial adenomatous
polyposis [FAP], MYH-associated polyposis, Lynch syn-
drome, and syndrome X) that develop dysplastic polyps and
pose an extremely high risk for colorectal cancer, and
hamartomatous syndromes (eg, juvenile polyposis, Cowden
disease, Peutz-Jeghers syndrome, and hyperplastic polyposis
syndrome) that pose a variable risk for colorectal cancer
development [15]. It is important to point out that many of
these syndromes carry risks for other cancers besides
colorectal cancer, and these cancers form the cornerstone of
surveillance strategies outside the colon (Table 1).
The only endoscopic modality used for secondary preven-
tion of colorectal cancer in the polyposis syndromes is
colonoscopy [2, 5•]. Criteria for surveilling patients and
categorizing them as polyposis patients include 1) the
presence of multiple polyps in the colon, 2) young age at
onset of colorectal cancer, particularly age less than 50 years,
3) a strong family history suggesting a familial syndrome,
and 4) evidence for a syndrome based on genetic testing [5•,
8•]. In some cases, it is difficult to ascertain the potential
future risk if the presenting phenotype is not clear. For
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Curr Colorectal Cancer Rep (2010) 6:24–29 25example MYH-associated polyposis is transmitted in an
autosomal recessive pattern so that a family history of
colorectal cancer often is absent, unlike with most other
polyposis syndromes [15]. Patients who present clinically
with multiple colonic adenomas likely have FAP or one of its
variants, and these patients often undergo total abdominal
colectomy, obviating the need for secondary prevention of
colorectal cancer. The phenotype of attenuated FAP or MYH-
associated polyposis might not be recognized as such, and the
initial primary tumor may be resected only regionally, as
would a sporadic colorectal tumor. Furthermore, there is no
precancerous phenotype for Lynch syndrome, thus other
methods of recognition must be used, including family
history, germline genetic testing, testing of the initial cancer
for immunohistochemical expression of the DNA mismatch
repair genes (Table 1), or testing for microsatellite instability
[5•, 8•]. Many Lynch syndrome patients undergo segmental
resection of the colon for their initial colorectal cancer
because the risk was not recognized, or in some cases in
which the risk was recognized, patients may have refused a
subtotal colectomy [5•]. Although colonoscopy has proven
effective in increasing survival in germline-identified Lynch
syndrome patients [2, 6], it does not result in 100% survival.
Thus, many patients with adenomatous syndromes retain
portions of their colon because segmental operations for their
initial colorectal cancer were performed as a result of low
suspicion or lack of recognition that they might have a
syndrome requiring a colectomy. Likewise, segmental resec-
tions often are the norm for some hamartomatous syndromes
with a variable risk for colorectal cancer, such as hyperplastic
polyposis syndrome [8•, 15]. Hyperplastic polyposis syn-
drome may give rise to large, proximally located hyperplastic
polyps that genetically follow a sessile serrated adenoma
pathway [18]. In many instances of hamartomatous syn-
dromes, secondary prevention via colonoscopy generally is
adequate because of the variable nature of cancer recurrence.
When the polyp burden is so high it prevents adequate and
thorough sampling for the occurrence of metachronous
cancer, colectomy should be strongly considered.
The timing of colonoscopy for secondary prevention in
familial syndromes is largely empiric; for most syndromes, it
is recommended annually (Table 2)[ 4••, 5•, 15]. However,
there have been cases in which yearly examinations showed
interval cancer development; these cases have occurred
mostly in patients with Lynch syndrome [5•]. The nature of
the genetic lesion in Lynch syndrome, loss of DNA
mismatch repair function, and subsequent targeting of
susceptible growth-regulating genes seem to drive cancer
development rapidly, to the point at which a polyp stage,
such as one would visualize with colonoscopy in a FAP
patient, is rarely seen [4••, 5•, 8•]. Furthermore, some Lynch
syndrome tumors are flat, lacking an exophytic form,
because of the lack of K-RAS activating mutations [8•, 19].
Thus, not only may cancers form rapidly in Lynch syndrome,
they may be missed on colonoscopy without careful
examination [19, 20••]. In the case of Lynch syndrome,
careful evaluation of each patient’sh i s t o r y ,a sw e l la sc a r e f u l
examination of the colon, may dictate the need for colono-
scopic examinations more frequently than once a year [5•].
There is at least one feature of Lynch syndrome that has led
Table 2 Suggested surveillance intervals for secondary prevention of colorectal cancer
Condition Interval
Sporadic colorectal cancer Clearing colonoscopy within 3–6 months of initial tumor, preferably preoperatively
if possible. Colonoscopy 1 year after initial tumor resection, and if exam is normal,
subsequent exam may be extended to 3 years. If the 3-year
exam is normal, colonoscopy may be extended to every 5 years
FAP and variants, including MYH-associated
polyposis
Annual colonoscopy and polypectomy of any remaining colon; if polyp burden is high,
surgical removal of remainder of colon should be considered
Lynch syndrome and variants (HNPCC) Annual colonoscopy of any remaining colon (at a minimum). Consideration should be
given to resecting remainder of colon in germline-positive patients
Familial type X Annual colonoscopy of any remaining colon
Juvenile polyposis syndrome Annual colonoscopy of any remaining colon; if polyp burden is high, surgical removal
of remainder of colon should be considered
Bannayan-Riley-Ruvalcaba syndrome Annual colonoscopy of any remaining colon
Cowden disease Annual colonoscopy of any remaining colon
Peutz-Jeghers syndrome Annual colonoscopy of any remaining colon; if polyp burden is high, surgical removal
of remainder of colon should be considered
Hyperplastic polyposis Annual colonoscopy of any remaining colon; if polyp burden is high, surgical removal
of remainder of colon should be considered
Hereditary mixed polyposis syndrome Annual colonoscopy of any remaining colon
FAP familial adenomatous polyposis, HNPCC hereditary nonpolyposis colorectal cancer
26 Curr Colorectal Cancer Rep (2010) 6:24–29experts to suggest yearly examinations [4••]: Lynch patients
with colorectal cancer, when compared stage to stage with
non-Lynch patients with colorectal cancer, have better
survival rates [8•]. The implication is that finding a cancer
at yearly colonoscopy still may afford better survival, even
though a cancer was discovered. Although the goal of
secondary prevention in a familial syndrome is to find
lesions at their earliest stage to prevent any deterioration in
patient survival, a metachronous tumor in a patient with
Lynch syndrome may still have a good outcome with
appropriate treatment, which should include colectomy.
Also, there is growing evidence that patients with Lynch
syndrome who develop colorectal cancer, as well as those
with sporadic colorectal cancer who show loss of DNA
mismatch repair within their tumors, do not respond to
standard 5-fluorouracil-based chemotherapy and have no
increase in survival [21–25]. Thus, secondary prevention
with colonoscopy followed by surgical resection if a lesion is
found is the mainstay of treatment for these high-risk
patients, as chemotherapy may not improve survival.
Chemoprevention has been used as an adjunct to
colonoscopic secondary prevention in some FAP patients
[26–28]. It should be pointed out that chemoprevention is
not a substitute for colectomy; however, there is evidence
that the number and size of adenoma precursors are smaller
in patients receiving cyclooxygenase (COX) inhibitors [26].
On cessation of COX inhibitors, the number and size of
polyps return to their pretreatment levels, indicating that the
drug must be present to have an effect. COX inhibitors do
not prevent the onset of precursor polyps in young FAP
patients [27], and it is not clear whether they prevent
metachronous tumor development in FAP patients.
Secondary Prevention of Sporadic Colorectal Cancer
Colorectal cancer patients who do not clearly fit a polyposis
syndrome are said to have sporadic disease, but their risk
for a metachronous colorectal cancer is elevated, likely to
the level of that of a noncancer patient with a young first-
degree relative with colorectal cancer (ie, a lifetime risk of
33%) [4••, 15]. Thus, surveillance by colonoscopy for
secondary prevention of recurrent tumor is paramount,
much like surveillance for primary or secondary prevention
in familial patients, as outlined earlier.
There are several reasons a metachronouscolorectalcancer
might developinapatient withsporadicdisease:1)thepatient
has an unrecognized familial syndrome; 2) residual tumor
may be present after resection by polypectomy or at surgery;
3) the patient has strong risk factors that modify the local
colonic environment, such as excessive serum growth
hormone in acromegaly; and 4) the patient has genetic risk
factors that do not fit into a familial syndrome.
To help recognize a familial syndrome, the clinician
should obtain a careful family history that takes into
account all types of cancers and polyps in the patient’s
family. Conditions such as acromegaly should be recog-
nized, but personal genetic factors are difficult to quantify.
Residual tumor has been described with colonoscopic
removal (snare polypectomy and endoscopic mucosal resec-
tion) as well as surgical removal, as a result of inadequate
margins or the presence of unrecognized extensive disease at
surgery. In the case of colonoscopic removal, re-colonoscopy
at very short intervals, such as every few weeks to every
2 months, is recommended to reevaluate the site [4••]. It is
also recommended that the site be identifiable, such as with
tattooing, for the next colonoscopy to ensure precise
observation of the mucosa at the resection site. Careful
attention must be paid to the resected pathologic specimen,
including looking for signs of vascular or lymphatic
invasion, margins free of tumor, and the tumor grade [7]. If
the pathology does not dictate a free-and-clear specimen,
then surgical resection is recommended, followed by
surveillance colonoscopy within a year. In the case of
recurrence after surgical resection, colonoscopic surveillance
should be combined with a radiologic examination, such as
abdominal CT scanning, because of potential recurrence of
tumor outside the luminal surface of the colon. At colono-
scopy, the surgical anastomosis should be identified; in some
cases, random biopsies of the anastomosis may be sent for
pathologic examination to rule out luminal recurrence.
Recommendations for secondary prevention of colorec-
tal cancer in patients with sporadic disease are based on the
length of time from the primary tumor occurrence [4••].
Patients—preferably before, if possible, but certainly after
their initial primary colorectal cancer—should have a
clearing colonoscopy to rule out synchronous tumors and
polyps. Within 1 year after the primary tumor resection,
another colonoscopy should take place, with careful
observation of the anastomosis as well as the remainder of
the mucosa for lesions that may have been missed on the
previous examination. If this examination is negative for
lesions in patients with sporadic disease, the next colono-
scopy generally may be performed 3 years after surgical
resection of the primary tumor. If that colonoscopy is
negative, then secondary prevention by colonoscopy may
be extended to every 5 years (Table 2)[ 4••].
Conclusions
Secondary prevention of colorectal cancer is principally by
colonoscopic visualization of any remaining colon in patients
with familial or sporadic colorectal cancer. Routine screening
modalities used for primary prevention have no role in
secondary prevention. A key role for the clinician is
Curr Colorectal Cancer Rep (2010) 6:24–29 27determining whether a patient has a familial syndrome, which
dictates annual surveillance by colonoscopy and subsequent
colectomy if a metachronous lesion is found, or has sporadic
disease, for which the patient can undergo surveillance at
gradually lengthening intervals. Clues to a familial form of
colorectal cancer should be actively ascertained. It is
important to identify patients with Lynch syndrome, as their
colorectal cancer may develop quite rapidly and their
examinations for secondary prevention surveillance may have
to be more frequent than once a year. Close follow-up by a
competenthealthcareprovider,suchasagastroenterologist,is
necessary to help prevent recurrence.
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